Point72 Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Point72 Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$962K	Sell	13,364 -420,055	-97%	-$23.9M	﹤0.01%	2781
2025 Q4	$18.3M	Buy	433,419 +309,761	+250%	+$17.3M	0.02%	946
2025 Q3	$7.04M	Buy	+123,658	New	+$4.09M	0.01%	938
2023 Q4	–	Sell	-101,372	Closed	-$906K	–	2594
2023 Q3	$906K	Buy	101,372 +99,848	+6,552%	+$961K	﹤0.01%	1358
2023 Q2	$13.1K	Buy	+1,524	New	+$16.3K	﹤0.01%	1866
2022 Q2	–	Sell	-29,587	Closed	-$2.39M	–	1556
2022 Q1	$2.39M	Sell	29,587 -1,233	-4%	-$182K	0.01%	849
2021 Q4	$6.25M	Sell	30,820 -4,320	-12%	-$937K	0.02%	622
2021 Q3	$9.47M	Buy	+35,140	New	+$8.45M	0.04%	505
2020 Q2	–	Sell	-1,045	Closed	-$280K	–	951
2020 Q1	$280K	Buy	+1,045	New	+$323K	﹤0.01%	700
2018 Q2	–	Sell	-1,473	Closed	-$2.35M	–	1119
2018 Q1	$2.35M	Buy	+1,473	New	+$1.9M	0.01%	716
2016 Q2	–	Sell	-613	Closed	-$127K	–	830
2016 Q1	$127K	Sell	613 -554	-47%	-$106K	﹤0.01%	692
2015 Q4	$295K	Sell	1,167 -8,000	-87%	-$1.65M	﹤0.01%	642
2015 Q3	$1.51M	Buy	+9,167	New	+$1.62M	0.01%	591

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Point72 Asset Management's NKTR Position: Q1 2026 in Review

Point72 Asset Management reduced its Nektar Therapeutics (NKTR) stake by 97% in Q1 2026, selling an estimated $23.9M and leaving 13,364 shares worth $962K. The position accounts for ﹤0.01% of the portfolio, ranked #2781.

Point72 Asset Management first reported a position in NKTR in Q3 2015 and has held it in 13 quarters since. The position peaked at $18.3M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Point72 Asset Management held 13,364 shares of Nektar Therapeutics worth $962K as of Q1 2026.
Point72 Asset Management sold 420,055 Nektar Therapeutics shares in Q1 2026, an estimated $23.9M.
Nektar Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2781 holding.
Point72 Asset Management first reported a position in Nektar Therapeutics in Q3 2015 and has held it in 13 quarters since.
Point72 Asset Management's Nektar Therapeutics position peaked at $18.3M in Q4 2025.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.